Update: Emory’s Radiotracer Axumin
Men now have a trustworthy new option for detecting recurring prostate cancer: PET imaging with the novel radiotracer fluciclovine (F18). Marketed by Blue Earth Diagnostics under the name Axumin, F18 was developed by Mark M. Goodman, PhD, professor, who co-directs Emory Radiology’s Molecular Imaging, Biomarker, and Probe Development Team, and Timothy Shoup, PhD, now at Massachusetts General Hospital. Professor David M. Schuster, MD, director of the Division of Nuclear Medicine and Molecular Imaging, led clinical validation.
More than 1,000 men already have benefited from PET imaging with Axumin at Emory. They chose Emory for both its expertise in nuclear medicine and molecular imaging and its personalized continuum of care.
Emory continues to explore Axumin’s clinical value through additional trials. A recently completed NIH-funded trial conducted in partnership with Grady Hospital examined tumor treatment outcomes based on conventional versus Axumin imaging. A current NIH-funded trial examines how well a PET/CT scan using Axumin compares with PET/CT using Gallium-68-PSMA for planning radiation treatments and enhancing positive outcomes for men with prostate adenocarcinoma. Participants are recruited at all Emory hospitals and Grady Hospital.
“We continue to be involved in the translation of new radiotracers for prostate and other cancers,” says Dr. Schuster. “Our goal is to bring the power of molecular imaging to all patients.”
More than 1,000 men already have benefited from PET imaging with Axumin at Emory. They chose Emory for both its expertise in nuclear medicine and molecular imaging and its personalized continuum of care.
Emory continues to explore Axumin’s clinical value through additional trials. A recently completed NIH-funded trial conducted in partnership with Grady Hospital examined tumor treatment outcomes based on conventional versus Axumin imaging. A current NIH-funded trial examines how well a PET/CT scan using Axumin compares with PET/CT using Gallium-68-PSMA for planning radiation treatments and enhancing positive outcomes for men with prostate adenocarcinoma. Participants are recruited at all Emory hospitals and Grady Hospital.
“We continue to be involved in the translation of new radiotracers for prostate and other cancers,” says Dr. Schuster. “Our goal is to bring the power of molecular imaging to all patients.”